NEW YORK, June 25 - Yamanouchi Pharmaceutical, the third largest drug maker in Japan, has signed a five-year subscription to Celera's Discovery System, the company's genomics database and bioinformatics tools.
The agreement allows researchers at Tokyo-based Yamanouchi access to all of Celera's genomics tools through the company's web-based interface. In addition to sequence data, the Discovery System includes software for searching and analyzing Celera's proprietary databases of human and mouse genomic information.
The companies did not disclose financial details, but in the past, Rockville, Md.-based Celera has charged pharmaceutical companies between $5 million and $15 million a year to use the databases.
Yamanouchi will apply the information in Celera's databases to its drug discovery efforts in adult and geriatric diseases, the company said.
The Yamanouchi deal adds to Celera's list of over 30 current subscribers, which include the University of California system, the Max Planck Society for Advancement of Science, the Karolinska Institute, and American Home Products.